Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Item
http://www.wikidata.org/entity/Q34035045
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialHIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Neurological Complications of HIV Infection.A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 t
P2860

Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Item
http://www.wikidata.org/entity/Q34035045
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
type
label
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
prefLabel
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698